Five major acquisitions in five months. Unilever, Danone, Herbalife — the world's largest FMCG and health companies are shopping the wellness and sports nutrition space at a pace not seen since 2019. This isn't coincidence. It's strategy.
Key Takeaways
- Danone acquires Huel for €1B — a direct bet on complete nutrition and DTC distribution
- Unilever buys Grüns for $1.2B — securing a premium position in the exploding gummy supplement format
- Herbalife acquires Ronaldo-backed Bioniq — entry into personalized, data-driven nutrition
- Five landmark deals in 5 months: this consolidation wave is structural, not cyclical
- Common thread: big CPG can't build loyal health audiences organically anymore — so they're buying them
Danone bets on complete nutrition
On March 23, 2026, Danone announced the acquisition of Huel for €1 billion. Huel is a UK-based complete nutrition brand — protein powders, ready-to-drink shakes, Hot & Savory meals, bars, supergreens — sold primarily DTC with strong online channels. The complete nutrition products market is estimated at $5.9 billion in 2025, with a projected CAGR of 6.5% over 10 years. Danone isn't just buying a product line. It's buying a DTC pipeline, an engaged subscriber base, and a position in a fast-growing segment where its legacy brands (Activia, Actimel) simply don't play.
Unilever and the gummy revolution
On June 1, 2026, Unilever announced the acquisition of Grüns for $1.2 billion. Grüns is a US-based nutritional gummy brand — a format that's been exploding since 2023. The logic: consumers, especially Millennials and Gen Z, are moving away from capsules and powders they associate with medicine cabinets. Gummies are palatable, social, and generate significantly higher repurchase rates. Unilever secured its position in this format before major pharma players can enter aggressively. The gummy supplement takeover isn't a fad — it's a category repositioning.
The strategy: why these deals, why now
These acquisitions share a common thread: large CPG groups are buying things they can no longer build organically. Specifically:
- Loyal DTC audiences. Huel and Grüns built their customer bases without distributors, through Instagram, TikTok, and online communities. Replicating that from scratch for a Danone or Unilever costs more than the acquisition price itself.
- Scientific or functional credibility. Bioniq (blood-test-based personalized nutrition), Symprove (clinical trial winner on gut microbiome), OZiva (USDA Organic clean label women's health) — these brands carry health legitimacy that Herbalife and HUL can't replicate with their current positioning.
- Access to fast-growing markets. HUL's acquisition of OZiva explicitly targets the booming Indian women's health market.
What this means for independent brands
The market is splitting in two. On one side, major brands — now backed by their new owners' resources — will accelerate in distribution, marketing, and innovation. On the other side, ultra-specialized niches that big groups can't acquire without destroying what makes them valuable: authenticity, community, radical positioning.
The hardest place to be is mid-size and undifferentiated. The Capstone Partners Q1 2026 report notes that assets without pricing power or a loyal health community are seeing their valuation multiples compress, while science-led, differentiated brands with high retention continue to attract premiums. The window to differentiate is narrowing.
What to watch next
- Function ($298M raised, $2.5B valuation) hasn't been acquired yet — it's the most likely next major target in the diagnostics-plus-supplements category.
- Metagenics/Symprove is the quietest deal but may be the most strategic: liquid probiotic formulation patents are a moat that capsule competitors can't cross.
- Pharma entry into gummies is coming. Bayer and Pfizer already have positions in vitamins. Unilever got there first.
- AI-personalized nutrition as the next front: Bioniq, Function, and multiple startups are converging on the same product — a supplement protocol built from biological data.